Critically evaluate the enforcement mechanism of UCPMP 2024, including the role of Ethics Officers and Ethics Committees, in ensuring compliance.
Q. Critically evaluate the enforcement mechanism of UCPMP 2024, including the role of Ethics Officers and Ethics Committees, in ensuring compliance. (15 marks, 250-350 words)
Notified by the Department of Pharmaceuticals on 12.03.2024, the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 replaced the voluntary 2015 Code to curb inducement-driven prescription [1][3]. Its enforcement machinery marks real progress, yet stops short of statutory teeth.
Strengths of the enforcement design
- Two-tier adjudication: complaints go to the Ethics Committee for Pharmaceutical Marketing Practices (ECPMP) at the association level, with appeal to an Apex Committee of the Department of Pharmaceuticals headed by Secretary (Pharma) [1][4].
- Company-level accountability: firms must designate an ethics compliance officer, file self-declarations of adherence, and publicly disclose expenditure on conferences and CME events [2].
- Clear prohibitions: gifts, monetary benefits and hospitality to doctors and their family members are barred, and companies are made liable for acts of their medical representatives [1].
- Demonstrated use: the Apex Committee's order of 23.12.2024 in the AbbVie Healthcare India matter shows the mechanism is operational, not merely paper [2].
Persisting weaknesses
- Non-statutory character: UCPMP remains an administrative Code, not an Act; penalties are limited to reprimand, recovery of the benefit given, and corrective media statements, with no direct penal sanction [1].
- Self-regulation risk: ECPMPs are constituted by industry associations, creating an evident conflict of interest, and non-member firms fall outside their reach [1][4].
- Complaint-driven model: enforcement depends on whistle-blowers rather than suo motu audit; the doctor's side is governed separately under the IMC (Professional Conduct) Regulations, 2002 [1].
UCPMP 2024 thus converts an unenforceable moral appeal into a functioning, government-supervised grievance system — a necessary and welcome advance. To make compliance durable, the way forward lies in giving the Code statutory backing, insulating Ethics Committees from association control, and linking marketing-expenditure disclosure to tax scrutiny. Aligned with SDG 3 and the right to health under Article 21, such reform would place patient welfare firmly above promotional interest.
(~330 words)
Sources: 1. Uniform Code of Pharmaceuticals Marketing Practices 2024 to prevent unethical marketing, PIB (2025) — notification date, prohibitions on gifts/hospitality, ECPMP–Apex appeal structure, penalty provisions, IMC Regulations 2002 2. Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Department of Pharmaceuticals — text of the Code: compliance officer, self-declaration, expenditure disclosure; Apex Committee order dated 23.12.2024 (AbbVie Healthcare India) 3. Uniform Code of Pharmaceutical Marketing Practices, PIB (2022) — voluntary status of UCPMP 2015 4. Uniform Code of Pharmaceutical Marketing Practices (UCPMP), PIB (2022) — association-constituted Ethics Committees and Apex Committee composition (Secretary and Joint Secretary, Pharma)